Delphia Therapeutics
Ben Stevens is a Senior Scientist at Delphia Therapeutics, having joined the company in January 2023. Prior to this role, Ben held various positions at Cedilla Therapeutics from December 2018 to January 2023, including Scientist I, Senior Research Associate, Research Associate II, and Research Associate I. Academic background includes a Master of Research in Biological and Biomedical Sciences and a Bachelor of Science in Biological and Biomedical Sciences, both earned at Cardiff Metropolitan University. Ben's graduate research focused on the effects of metabolic stimuli on monocyte/macrophage inflammatory responses and morphology, supported by a KESS II Scholarship.
This person is not in any teams
Delphia Therapeutics
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.